Dr. John Cush RheumNow
2 years 10 months ago
RheumNow Podcast – Bill of Rights
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow. Two major reports on fatigue and fibromyalgia misfired, and "ankylosing spondylitis" is sent to the Rheumatology dead word cemetery.
https://t.co/lYtunY4cqd https://t.co/yNPqhPx5y3
Dr. John Cush RheumNow
2 years 10 months ago
Gender Gap Confirmed for TNF Inhibitor Response in Axial SpA
Men with axial spondyloarthritis (axSpA) were more likely than women to obtain substantial relief with tumor necrosis factor (TNF) inhibitors, a multinational study indicated.
https://t.co/ye5iReGLMG https://t.co/goKe0TuYqz
Dr. John Cush RheumNow
2 years 10 months ago
Empathy is the hard part.
The rest is mechanics. We're not wired to walk in someone else's shoes, it's not our first instinct.
Showing up with empathy is difficult, hard to outsource and will wear you out. But it's precisely what we need from you. - Seth Godin… https://t.co/U8Ou3WwBmC https://t.co/C4aAVovHDH
Dr. John Cush RheumNow
2 years 10 months ago
SGLT2 inhibitor (empagliflozin) given in a lupus mouse (MRL/lpr) model showed a renoprotective effect suggesting the value of non-immunosuppressive therapies to improve renal function. Showed less -dsDNA Abs, proteinuria, renal nephritis damage https://t.co/VfLUbCjmMt https://t.co/EAsvfzRgm1
EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). AAV recommendations were last published in 2016, and since, research and clinical trials have advanced our understanding of AAV. A EULAR task force of 20 experts from 16 countries, reviewed the literature and developed four overarching principles and 17 recommendations.
This week I reached out to many leaders in rheumatology and asked: who are the great women in rheumatology who should be recognized? This was prompted by a smart article in Annals of Rheumatic Disease written by Drs. Tuhina Neogi (Boston) and Nicola Dalbeth (N. Zealand), entitled "Where are the women ‘Heroes and Pillars of Rheumatology’?
Dr. John Cush RheumNow
2 years 10 months ago
NVC in 1356 #SSc registry pts classified as early, active or‘late. Late pattern seen in 40%: signific. assoc w/ dcSSc (OR=1.96), ILD (OR=1.29), renal crisis (OR=3.46), digital ulcer (OR=1.29), & topoisomerase I Abs (OR=1.39) https://t.co/RgET0HbImf https://t.co/Ex3nKto6JW
Dr. John Cush RheumNow
2 years 10 months ago
Cross-sectional study 365 RA pts showed eating half a pizza >1 time/wk (vs. ≤2 times/mo) was assoc w/ 70% less Dz activity; esp w/ more severe RA (80%) (benefit likely due to mozzarella & olive oil). YES, this was an italian study... https://t.co/1yHtS1wrtn https://t.co/xoxKK6ujdk
Dr. John Cush RheumNow
2 years 10 months ago
ICYMI: Bimekizumab is Coming…in Third Place
Of the many exciting advancements for patients with psoriatic arthritis at ACR23 one upcoming therapy stood out: the dual IL-17A/F inhibitor bimekizumab.
https://t.co/rhyEuyCjQI https://t.co/vbRs2144We
Dr. John Cush RheumNow
2 years 10 months ago
ICYMI: Methotrexate: shall we split up?
Methotrexate (MTX) is widely used in rheumatic diseases yet poses common tolerance issues, especially for the oral form; and bioavailability is known to be limited for doses over 15mg.
https://t.co/EQV2LeaaGB https://t.co/bD2zJbXETv
Dr. John Cush RheumNow
2 years 10 months ago
RHEUMATOLOGIST SURVEY QUESTION - Is TYK2 part of the Janus Kinase family?
Click here to answer >> https://t.co/7SgvYqFe1W
Dr. John Cush RheumNow
2 years 10 months ago
Promising Therapies for Sjogren's
Dr. Yuz Yusof discusses abstracts 1634 at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/qwRRf0sYhj https://t.co/zZACPJ96NM
A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy.
